FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
August 16 2021 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat
Cotroneo, Chief Financial Officer, and the appointment of Juan
Graham in that role. Pat will continue as Chief Financial Officer
through September 6, 2021, and will remain with FibroGen through
March 31, 2022 serving as Executive Advisor to the CEO to ensure a
smooth transition.
“On behalf of the board, shareholders, and our employees, I want
to thank Pat for his contributions as Chief Financial Officer and
dedicated service over the past 21 years,” said Enrique
Conterno, Chief Executive Officer, FibroGen. “With his leadership,
FibroGen transitioned from a private to public company, and from a
development stage to commercial stage company.”
Juan Graham will become Chief Financial Officer effective
September 7, 2021, overseeing all finance operations. Mr. Graham
has nearly two decades of global biopharmaceutical financial
management and strategic planning experience.
“Juan’s extensive financial leadership and strategic planning
come at a critical time for FibroGen as we look ahead to multiple
significant clinical milestones,” said Mr. Conterno. “The depth and
breadth of his financial experience is an ideal fit, and we are
thrilled to welcome him to the FibroGen team.”
"I am excited about joining FibroGen and helping deliver the
Company's vision in the advancement of breakthrough science and
novel medicines in areas of high unmet clinical need for patients
around the world," said Mr. Graham.
Mr. Graham was most recently Global Chief Financial Officer /
Vice President Finance Supply Chain at Johnson & Johnson, Inc.
Juan spent the last 20 years at Johnson & Johnson, Inc. in a
variety of roles including VP Finance & Business Development,
Senior Finance Director, J&J Development Corporation / J&J
Innovation, and Finance Director, Mergers & Acquisitions to
name a few. Juan received his bachelor’s degree in Business
Administration from the Monterrey Institute of Technology and
Higher Education. He received his Master’s in Business
Administration from the McGill University Graduate School of
Business.
About FibroGenFibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines for the treatment of unmet needs. The
Company is currently developing and commercializing roxadustat, an
oral small molecule inhibitor of HIF prolyl hydroxylase activity,
for anemia associated with chronic kidney disease (CKD). Roxadustat
is also in clinical development for anemia associated with
myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia
(CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in
clinical development for the treatment of locally advanced
unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy
(DMD), and idiopathic pulmonary fibrosis (IPF). For more
information, please visit www.fibrogen.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding our strategy, future plans and
prospects, including statements regarding the development and
commercialization of the company’s product candidates, the
potential safety and efficacy profile of our product candidates,
our clinical programs and regulatory events, and those of our
partners. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations
and contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and
potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2020 and our Quarterly Report on Form 10-Q for
quarter ended June 30, 2021 filed with the Securities and Exchange
Commission (SEC), including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contacts:FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor Relations415.978.1434mtung@fibrogen.com
Media:GCI HealthFibroGenMedia@gcihealth.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024